Akoustis Technologies, Inc. AKTS · Stock Open Akoustis Technologies, Inc. in new tab
Akoustis Technologies, Inc. Analysis (AKTS)
Is Akoustis Technologies, Inc. a good investment? Akoustis Technologies, Inc. (AKTS) is currently trading at 23.89 USD. Market analysts have a consensus price target of 34.38 USD. This suggests a potential upside from current levels.
Earnings Schedule: Akoustis Technologies, Inc. is expected to release its next earnings report on Aug. 10, 2026. The market consensus estimate for Forward EPS is -1.97.
Investor FAQ
Does Akoustis Technologies, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Akoustis Technologies, Inc.?
Akoustis Technologies, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 10, 2026. The company currently has a trailing EPS of -1.21.
Company Profile
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Community Discussion